Welcome to Pharmaceutical Markets.com

Latest News

• NICE final approval extends use of Roche's MabThera

  The National Institute for Health and Clinical Excellence (NICE) has issued final guidance recommending Roche's MabThera (rituximab) as an option when used in combination with a wide range of chemotherapy treatments for advanced follicular lymphoma, PharmaTimes.com reports. [FULL STORY]

• Watson and Amphastar launch Lovenox copy on court ruling

  Momenta has lost its exclusive hold on the generic Lovenox market, at least temporarily, fiercepharma.com reports. [FULL STORY]

• J&J wins jury verdict over Levaquin warning

  J&J can not be held liable for the tendon injuries to a 78-year-old man who said that the company did not properly warn of the risks of its antibiotic Levaquin, a Minnesota jury said, Bloomberg reports. [FULL STORY]

• Biogen and Elan conduct Phase IIIb study for SPMS treatment

  Biogen and Elan said on Thursday that it is conducting a global Phase IIIb study, ASCEND, to evaluate the effectiveness of TYSABRI as a treatment for secondary-progressive multiple sclerosis or SPMS, RTTNews reports. [FULL STORY]

• Study finds no link between Merck's Gardasil and autoimmune disorders

  The human papillomavirus (HPV) vaccine Gardasil does not trigger autoimmune disorders such as rheumatoid arthritis, lupus, type I diabetes or multiple sclerosis, according to a two-year study that included nearly 190,000 girls and women, HealthDay News reports. [FULL STORY]